Large data sets like SEER need better quality control checks and researchers and clinicians who use these data sets should also consider using secondary data analyses that answer specific research questions. This is the advice of a senior urologist following the removal of the PSA data.
A recent quality control check by the National Cancer institute (NCI) of the Surveillance, Epidemiology and End Results (SEER) and SEER-Medicare programs found that a significant number of these values were incorrect. Subsequently, NCI removed these PSA values from the data sets. A urologist at Vanderbilt University, David F. Penson, MD, MPH, has contributed an editorial in The Journal of Urology, which explores the ramifications of this elimination for research scientists, clinicians, and healthcare administrators who depend on these data sets to make healthcare decisions. Additionally, Dr Penson encourages researchers to collect primary data and create sub-group data sets to fill-in some of the data gaps that huge data sets like SEER have.
Read the report on ScienceDaily: http://bit.ly/1FreYVr
Study: SGLT2is Should Be Continued Despite Initial eGFR Decline in Patients With HFmrEF/HFpEF
December 6th 2023Despite an initial drop in estimated glomerular filtration rate (eGFR) after 1 month of dapagliflozin, researchers say this is not associated with subsequent risk of cardiovascular or kidney events for patients with heart failure with mildly reduced ejection fraction (HFmrEF) or preserved ejection fraction (HFpEF).
Read More
Exclusive Telemedicine Use Linked to Less Favorable Glycemic Outcomes for T2D Endocrinology Care
December 6th 2023Adults with type 2 diabetes (T2D) undergoing endocrinology care are more likely to experience less favorable hemoglobin A1c improvements if they only use telemedicine compared with patients using in-person care or a mix of both.
Read More